Finance

Lists
4AB:ETR
AbbVie Common Stock
258,70 €
+0,82%
(+2,10) 1D
20-ноя., 09:16:11 GMT+1  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 4AB...
Open
260,90 €
High
260,90 €
Low
258,70 €
Mkt. cap
501,19 млд
Avg. vol.
651,00
Volume
82,00
52-wk high
272,20 €
52-wk low
162,85 €
No. of employees
57 миң
Open
260,90 €
High
260,90 €
Low
258,70 €
Mkt. cap
501,19 млд
Avg. vol.
651,00
Volume
82,00
52-wk high
272,20 €
52-wk low
162,85 €
No. of employees
57 миң
News stories
From web sources and news partners
Euronext Markets: Real-time Stock Market Data | live
Euronext Markets: Real-time Stock Market Data | live
·
17 саат мурун
AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco
ad-hoc-news.de
ad-hoc-news.de
·
18 саат мурун
AbbVie stock: Piper Sandler raises target to USD 349
Pharmaceutical Executive
Pharmaceutical Executive
·
18 саат мурун
DISCO, AbbVie Sign AND-Gated Bispecific Deal Worth Up to $2.5B
Puerto Rico Federal Affairs Administration (.gov)
Puerto Rico Federal Affairs Administration (.gov)
·
2 күн мурун
NEW of PRFAA
Profile
AbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. AbbVie produces drugs to treat a wide range of medical issues. The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000. The name "AbbVie" is derived from a combination of "Abbott", the name of its former parent company, with "vie", intended as a reference to a Latin root meaning 'life'. Wikipedia
About AbbVie Common Stock
CEORobert A. Michael
Employees57 миң
Founded2012-ж., 10-апр.
HeadquartersСевер Чикаго, Иллинойс, Америка Кошмо Штаттары
SectorHealth Care
Industry-
Websiteabbvie.com
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
16,62 млд
15,00 млд
16,99 млд
17,40 млд
Cost of goods sold
4,55 млд
4,22 млд
4,29 млд
4,28 млд
Cost of revenue
4,55 млд
4,22 млд
4,29 млд
4,28 млд
Research and development expenses
2,58 млд
2,47 млд
2,34 млд
2,45 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,82 млд
3,49 млд
3,55 млд
3,80 млд
Operating expense
6,40 млд
5,96 млд
5,90 млд
6,23 млд
Total operating expenses
10,95 млд
10,18 млд
10,19 млд
10,51 млд
Operating income
5,67 млд
4,82 млд
6,80 млд
6,89 млд
Other non operating income
120,00 млн
-3,00 млн
-55,00 млн
37,00 млн
EBT including unusual items
2,67 млд
1,04 млд
4,28 млд
4,83 млд
EBT excluding unusual items
5,12 млд
4,19 млд
6,07 млд
6,19 млд
Income tax expense
853,00 млн
342,00 млн
662,00 млн
609,00 млн
Effective tax rate
31,97%
32,92%
15,47%
12,61%
Other operating expenses
-
-
-
-18,00 млн
Net income
1,82 млд
695,00 млн
3,61 млд
4,22 млд
Net profit margin
10,93%
4,63%
21,27%
24,24%
Earnings per share
2,71
2,65
3,65
3,82
Interest and investment income
59,00 млн
72,00 млн
67,00 млн
102,00 млн
Interest expense
-714,00 млн
-717,00 млн
-746,00 млн
-802,00 млн
Net interest expenses
-655,00 млн
-645,00 млн
-679,00 млн
-700,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
7,66 млд
6,76 млд
8,68 млд
8,75 млд
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google колдонмолору